Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN)
| 62.72 Delayed Data As of Sep 25 |  +0.47 / +0.76%Today’s Change | 26.56 Today|||52-Week Range 78.75 | +15.21% Year-to-Date |
Latest BHVN News | Press Releases
| Biohaven launches early-stage study of oral migraine med zavegepant Sep 10 / Seeking Alpha - Paid Partner Content | Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2020 Update Sep 04 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 62.25 |
| Today’s open | 62.00 |
| Day’s range | 60.99 - 63.56 |
| Volume | 588,910 |
| Average volume (3 months) | 660,617 |
| Market cap | $3.8B |
Data as of 3:59pm ET, 09/25/2020
Growth & Valuation
| Earnings growth (last year) | -77.39% |
| Earnings growth (this year) | -5.22% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TPTXTurning Point Therap... | +3.07 | +3.68% |
| CCXIChemoCentryx Inc | +1.05 | +2.03% |
| ---- | ||
| FOLDAmicus Therapeutics ... | -0.01 | -0.07% |
Data as of 4:00pm ET, 09/25/2020
Financials
| Next reporting date | November 11, 2020 |
| EPS forecast (this quarter) | -$2.53 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$528.8M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New Haven, Connecticut |
Forecasts
